INS and metabolic dysfunction-associated steatotic liver disease: Therefore, a non-invasive way to assess the long-term consequences of insulin and lipid impairment could be done through the screening of non-alcoholic fatty liver disease (NAFLD, the hepatic manifestation of MES and IR), i.e., through the use of Fibroscan (11).